Savant Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Savant Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	7,286 +5,702	+360%	+$771K	﹤0.01%	841
2026 Q1	$202K	Buy	+1,584	New	+$198K	﹤0.01%	1412

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Savant Capital's XBI Position: Q2 2026 in Review

Savant Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 360% in Q2 2026, buying an estimated $771K and bringing the position to 7,286 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Savant Capital first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Savant Capital held 7,286 shares of State Street SPDR S&P Biotech ETF worth $1.1M as of Q2 2026.
Savant Capital bought 5,702 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $771K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #841 holding.
Savant Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.